You are here

Share:

Search Technologies

Showing 1-20 of 38 results found

Bacteriophage Based-Vaccine System

Scientists at the National Cancer Institute (NCI) developed an engineered bacteriophage lambda () vector for displaying antigens to be used as a vaccine in treatment of cancers and infectious diseases. The NCI seeks licensing and/or co-development research collaborations for further development of the Bacteriophage based-vaccine system.

Biomarker Analysis Software for High-Throughput Diagnostic Multiplex Data

Extracellular vesicles (EVs) are lipid spheres released from cells. EVs contain proteins that can serve as diagnostic biomarkers indicating the cell state at time of release. Improved detection and phenotyping of EVs and their protein cargo could lead to better cancer diagnostic and prognostic tests, as well as improved therapeutic uses. The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for a software package that performs high-throughput multi-dimensional analysis of EV biomarkers.

Denoising of Dynamic Magnetic Resonance Spectroscopic Imaging Using Low Rank Approximations in the Kinetic Domain

Scientists at The National Cancer Institute (NCI) and The National Institute of Neurological Disorders and Stroke (NINDS) have invented a method of imaging glucose metabolism in vivo using MRI chemical shift imaging (CSI) experiments that relies on a simple, but robust and efficient, post-processing procedure by the higher dimensional analog of singular value decomposition, tensor decomposition. This new technology is denoising software for MRIs that significantly improves the measurement of low-intensity signals without the need for dynamic nuclear polarization (DNP). The scientists seek research co-development partners and/or licensees for their invention.

Automated Cancer Diagnostic Tool of Detecting, Quantifying and Mapping Mitotically-Active Proliferative Cells in Tumor Tissue Histopathology Whole-Slide Images

The National Cancer Institute (NCI) seeks research, co-development, or licensing partners for software that uses computational approaches in cancer diagnosis. NCI researchers have recently developed a computational approach for detecting, quantifying, and mapping Mitotic Hotspots in whole slide images of tumor tissue. This technology has demonstrated high reproducibility that is unaffected by diagnostic skill or fatigue, allowing standardization of tumor cell proliferation assessment across institutions.

Mitotic Figures Electronic Counting Application for Surgical Pathology

National Cancer Institute (NCI) researchers have developed a novel software tool for uniform recording of Mitotic Figure (MF) counts via conventional and/or digital microscopy. With this technology, diagnostic centers can standardize electronic recording, summation, and transcription of clinical data during surgical pathology examination. NCI seeks licensing partners to further develop this application for use in diagnosis and detection of malignant cancers.

New Insect Sf9-ET Cell Line for Determining Baculovirus Titers

The National Cancer Institute (NCI) seeks licensing partners for a novel modified insect cell line, Sf9-ET, that can quickly and efficiently determine baculovirus titers during the expression of recombinant proteins from a baculovirus-based protein expression system.

Transperineal Ultrasound-Guided Prostate Biopsy

The National Institutes of Health (NIH) Clinical Center (CC) seeks Cooperative Research and Development and/or license agreements for Transperineal Ultrasound-Guided Prostate Biopsy

Micro-Dose Calibrator for Pre-clinical Radiotracer Assays

Pre-clinical radiotracer biomedical research involves the use of compounds labeled with radioisotopes, including radio-ligand bio-distribution studies, cell binding studies, immune cell labeling techniques, and α-based therapies. Before this Micro-Dose Calibrator, measurement of pre-clinical level dosage for small animal studies was inaccurate and unreliable. This dose calibrator is a prototype ready for customer testing and scale-up. It is designed to accurately measure radioactive doses in the range of 50 nCi (1.8 kBq) to 100 µCi (3.7 MBq) with 99% precision. The NCI seeks co-development or licensing to commercialize it. Alternative uses will be considered.

Clinical Imaging with Acoustic Wave or Photoacoustic Tomosynthesis

Ultrasound-based cancer screening and biopsy imaging technique are a critical clinical need. Ultrasound based biopsy imaging can provide a real-time modality for lower cost that is comparable to, or complimentary to MRI imaging. Researchers at the NIH Clinical Center seek licensing and/or co-development research collaborations for Tissue Characterization with Acoustic Wave Tomosynthesis.

Pages